Effect of capecitabine combined with chemotherapy regimens in treatment of postoperative metastatic and recurrent gastric cancer
ZHOU Wenguang1, YING Haojie1, ZHANG Xiaomin2
1. Department of General Surgery, Zibo Medical District, the 960th Hospital of the Joint Logistics Support Force of the PLA, Zibo 255300, China; 2. Department of Nephrology, Affiliated Hospital of Binzhou Medical College, Binzhou 256600,China
Abstract：Objective To compare the survival time, carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and carbohydrate antigen 724 (CA724) of patients with metastatic and recurrent gastric cancer after capecitabine combined with paclitaxel and oxaliplatin respectively.Methods A total of 101 patients with postoperative recurrence or metastasis of gastric cancer admitted to the 960th Hospital of the joint logistics support force of the PLA from January 2019 to January 2021 were selected. According to the treatment methods, the patients were divided into capecitabine combined with paclitaxel regimen group (T group, n=51) and capecitabine combined with oxaliplatin regimen group (O group, n=50). The short-term curative effects, the levels of tumor markers before and after chemotherapy, the incidence of adverse reactions between the two groups were compared respectively. The patients were followed up to observe the long-term efficacy.Results There was no significant difference in the total effective rate of short-term clinical efficacy between the two groups, and there were no significant level differences in serum CEA [(21.19±1.60) ng/mL vs (20.83±1.53) ng/mL], CA199[(53.94±3.26) U/mL vs (53.79±3.26) U/mL] and CA724 [(27.11±1.57) U/mL vs (27.48±1.61) U/mL]between the two groups after chemotherapy. By January 2022, the median survival time of group T was 13 months (95% CI: 11.932~14.068), and 13 months (95% CI: 11.932~14.068) for group O. Log-rank test showed that there was no significant difference in Kaplan-Meier curve between the two groups (Log χ2=0.443, P=0.506). There were no significant differences in the incidence of grade 1-2 gastrointestinal reactions, abnormal liver and kidney function, hand-foot syndrome, blood or lymphatic system symptoms, and incidence of hair loss, grade 3-4 abnormal liver and kidney function, and hair loss between the two groups (P>0.05). The toxic and side effects in both groups were relieved after symptomatic treatment.Conclusions Capecitabine combined with paclitaxel and capecitabine combined with oxaliplatin are both characterized by good curative effect in patients with postoperative metastasis and recurrence of gastric cancer, and their safety is similar.
Wang J, Wang Y, Wang J, et al. DEAD-box helicase 56 functions as an oncogene promote cell proliferation and invasion in gastric cancer via the FOXO1/p21 Cip1/c-Myc signaling pat hway[J]. Bioengineered, 2022, 13(5):13970-13985.
[2]
Chiarello M M, Fico V, Pepe G, et al. Early gastric cancer: a challenge in western countries [J]. World J Gastroenterol, 2022, 28(7):693-703.
[3]
Wang G, Jiang X. Effect of precede-proceed-model-based health education on the life quality and 5-HTT gene expression of patients with gastric cancer after surgery[J]. Cell Mol Biol (Noisy-le-grand), 2022, 67(6): 242- 248.
[4]
Cheng X, Wu D, Xu N, et al. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol[J]. BMC Cancer, 2021, 21(1):56.
[5]
胃癌规范化诊疗指南(试行)[J]. 慢性病学杂志, 2013, 14(8):561-568.
[6]
Litière S, Isaac G, Vries E G, et al. RECIST 1.1 for response evaluation apply not only to chemotherapy- treated patients but also to targeted cancer agents: a pooled database analysis[J]. J Clin Oncol, 2019, 37(13): 1102-1110.
[7]
Mohile S G, Mohamed M R, Xu H, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study[J]. Lancet, 2021, 398(10314):1894-1904.
[8]
Ajani J A, D'Amico T A, Bentrem D J, et al. Gastric cancer, version 2.2022, nccn clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2):167-192.
[9]
Norwood D A, Montalvan E E, Dominguez R L, et al. Gastric cancer: emerging trends in prevention, diagnosis, and treatment[J]. Gastroenterol Clin North Am, 2022, 51(3):501-518.
[10]
Zheng Z, Shang Y, Xu R, et al. Ubiquitin specific peptidase 38 promotes the progression of gastric cancer through upregulation of fatty acid synthase[J]. Am J Cancer Res, 2022, 12(6):2686-2696.
[11]
Kato H, Kishiwada M, Hayasaki A, et al. Role of serum carcinoma embryonic antigen (CEA) level in localized pancreatic adenocarcinoma: CEA level before operation is a significant prognostic indicator in patients with locally advanced pancreatic cancer treated with neoadjuvant therapy followed by surgical resection: a retrospective analysis[J]. Ann Surg, 2022, 275(5):e698-707.
[12]
Wang H, Jin W, Wan C, et al. Diagnostic value of combined detection of CA72-4, CA19-9, and carcinoembryonic antigen comparing to CA72-4 alone in gastric cancer: a systematic review and meta-analysis[J]. Transl Cancer Res, 2022, 11(4):848-856.
[13]
Adams R A, Fisher D J, Graham J, et al. Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial[J]. J Clin Oncol, 2021, 39(33):3693-3704.
[14]
Matsumoto R, Yoshii T, Egawa S, et al. Local suppression effect of paclitaxel-impregnated hydroxyapatite/ collagen on breast cancer bone metastasis in a rat model[J]. Spine Surg Relat Res, 2021, 6(3):294-302.
[15]
Li Q J, He M K, Chen H W, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial[J]. J Clin Oncol, 2022, 40(2):150-160.
2023, Vol. 34 
